BSE Live
Mar 30, 16:01Prev. Close
10.95
Open Price
10.62
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 30, 15:59Prev. Close
10.94
Open Price
10.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
10.30 (117)
| Balance Sheet of Syncom Formulations (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 5.34 | 5.08 | |
| Total Share Capital | 5.34 | 5.08 | |
| Reserves and Surplus | 17.13 | 10.19 | |
| Total Reserves and Surplus | 17.13 | 10.19 | |
| Total Shareholders Funds | 22.47 | 15.27 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 3.63 | 5.48 | |
| Deferred Tax Liabilities [Net] | 3.58 | 2.67 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 7.21 | 8.14 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 1.03 | 6.35 | |
| Trade Payables | 7.87 | 5.04 | |
| Other Current Liabilities | 0.93 | 1.91 | |
| Short Term Provisions | 3.47 | 0.94 | |
| Total Current Liabilities | 13.30 | 14.24 | |
| Total Capital And Liabilities | 42.98 | 37.65 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 16.91 | 15.14 | |
| Intangible Assets | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.03 | 0.00 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 16.94 | 15.14 | |
| Non-Current Investments | 0.04 | 0.04 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.11 | |
| Total Non-Current Assets | 16.98 | 15.29 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 5.41 | 4.32 | |
| Trade Receivables | 15.31 | 13.30 | |
| Cash And Cash Equivalents | 0.18 | 0.21 | |
| Short Term Loans And Advances | 5.10 | 4.53 | |
| OtherCurrentAssets | 0.00 | 0.00 | |
| Total Current Assets | 26.00 | 22.36 | |
| Total Assets | 42.98 | 37.65 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 0.10 | 0.05 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 0.14 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 0.61 | 0.66 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | 35.20 | 26.88 | |
| Other Earnings | -- | -- | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 0.08 | 0.08 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | -- | -- | |
| Non-Current Investments Unquoted Book Value | 0.04 | 0.04 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- |
26.11.2025
Syncom Formula Consolidated September 2025 Net Sales at Rs 121.72 crore, up 18.96% Y-o-Y
24.11.2025
Syncom Formula Standalone September 2025 Net Sales at Rs 121.44 crore, up 19.65% Y-o-Y
22.08.2025
Syncom Formula Standalone June 2025 Net Sales at Rs 116.55 crore, up 34.22% Y-o-Y
20.05.2025
Syncom Formula Consolidated March 2025 Net Sales at Rs 148.88 crore, up 99.64% Y-o-Y
26.11.2025
Syncom Formula Consolidated September 2025 Net Sales at Rs 121.72 crore, up 18.96% Y-o-Y
24.11.2025
Syncom Formula Standalone September 2025 Net Sales at Rs 121.44 crore, up 19.65% Y-o-Y
22.08.2025
Syncom Formula Standalone June 2025 Net Sales at Rs 116.55 crore, up 34.22% Y-o-Y
20.05.2025
Syncom Formula Consolidated March 2025 Net Sales at Rs 148.88 crore, up 99.64% Y-o-Y
30.03.2026
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth